Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Abstract: A projectile having a spin stabilized gyroscopically stable flight path due to a base flange. With the base flange, the aerodynamic overturning moment about the center of gravity is reduced to increase the gyroscopic stability factor for stable flight. In one application, a medium-caliber untethered human electro-muscular incapacitation (HEMI) projectile has improved effectiveness due to its stable flight from launch to targets. Other applications for damping resulted in significant improvement in ground dispersion of 40 mm projectiles. The increased stability and increased aerodynamic damping reduce coning motion during flight which ensures that the projectile arrives at the target with greater accuracy, and with its nose oriented for effective incapacitation of the target.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: A light shaping assembly comprises a printed circuit board (PCB), a two-dimensional (2D) array formed of a plurality of rows, each row comprising a plurality of light sources mounted on the PCB, and a Fresnel lens. The Fresnel lens redirects a light beam emitted by each light source at an angle that increases as a function of a distance between each light source and a selected point on the PCB, so that the light beams emitted by the light sources are collectively directed toward a common target.

Abstract: A device comprises an enclosure having a rear opening adapted to receive a light beam from a light source, a front opening adapted to emit a modified light beam, and internal walls extending between the rear opening and the front opening. The light beam is modified according to a perimeter of the front opening. A light shaping assembly comprises a two-dimensional array formed of a plurality of such devices, each one of the plurality of devices being adapted to receive a light beam from a corresponding light source.

Abstract: Control instructions are transmitted to receivers by modulating light sources to generate light beams that are modulated with digital data streams for inducing control instructions in the light beams. Each light beam is applied to a pixel shaper element of a pixel shaper assembly to produce a light pixel, each light pixel carrying the control instructions of the light beam, each light pixel having a perimeter defined by the pixel shaper element. The pixel shaper assembly combines the light pixels into an image without significant overlap or voids between the light pixels. The light pixels are directed toward a projector lens for transmission toward the receivers. In a receiver, an optical receiver detects a light pixel. A controller decodes the control instructions received in the detected light pixel and uses the control instructions to control a function of the receiver.

Abstract: A light shaping assembly comprises a printed circuit board (PCB) and a two-dimensional (2D) array formed of a plurality of rows, each row comprising a plurality of light sources mounted on the PCB, each light source comprising a pair of supporting pins for mounting the light source on the PCB. The supporting pins of each light source are bent at an angle that is increasing as a function of a distance between each light source and a selected point on the PCB so that light beams emitted by the light sources are collectively directed toward a common target.

Abstract: A combination comprises at least one lens and at least one prism. The at least one lens and the at least one prism are in an optical path of a corresponding at least one light source. The combination is configured to direct light radiating from the at least one light source toward a projector lens.

Abstract: Embodiments of the present invention include a lighting fixture(s), a computer program product and a computer-implemented method that include program code executed by a processor(s) that obtains a request to implement a specified lighting pattern in the lighting fixture(s). Each lighting fixture includes effect lighting communicatively coupled to the processor(s) and functional lighting (oriented to illuminate a surface below the lighting fixture) communicatively coupled to the processor(s). The program code identifies the specified lighting pattern in a memory communicatively coupled to the processor(s), which includes a sequence for illuminating a portion of the effect lighting elements. The processor(s) executes the specified lighting pattern in the lighting fixture(s).

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Embodiments of the present invention include a lighting fixture(s), a computer program product and a computer-implemented method that include program code executed by a processor(s) that obtains a request to implement a specified lighting pattern in the lighting fixture(s). Each lighting fixture includes effect lighting communicatively coupled to the processor(s) and functional lighting (oriented to illuminate a surface below the lighting fixture) communicatively coupled to the processor(s). The program code identifies the specified lighting pattern in a memory communicatively coupled to the processor(s), which includes a sequence for illuminating a portion of the effect lighting elements. The processor(s) executes the specified lighting pattern in the lighting fixture(s).

Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.